Protein linked to cancer acts as a viscous glue in cell division

July 07, 2020

TROY, N.Y. -- An over-abundance of the protein PRC1, which is essential to cell division, is a telltale sign in many cancer types, including prostate, ovarian, and breast cancer. New research, published online today in Developmental Cell, shows that PRC1 acts as a "viscous glue" during cell division, precisely controlling the speed at which two sets of DNA are separated as a single cell divides. The finding could explain why too much or too little PRC1 disrupts that process and causes genome errors linked to cancer.

"PRC1 produces a viscous frictional force, a drag that increases with speed," said Scott Forth, an assistant professor of biological sciences and member of the Center for Biotechnology and Interdisciplinary Studies at Rensselaer Polytechnic Institute. "The friction it produces is similar to that of water - if you try to move your hand through water slowly, you move easily, but if you push your hand fast, the water pushes back hard."

At the nitty-gritty level of DNA, motor proteins, and microtubules, biology takes its cue from physics. During the mitotic stage of cell division, a single cell must copy its DNA into two identical sets, and then rapidly and efficiently pull that DNA apart into two new daughter cells. It's a physical act, and the cellular structure that does it, the mitotic spindle, is a machine that uses mechanical forces - push, pull, and resistance - to complete the task.

"We think the force PRC1 produces is integrating and dampening out cellular motions as the DNA is separated so that ultimately, you get the correct rate of chromosome segregation," Forth said. But if the process goes awry, the cells end up working with the wrong instruction manual, which can lead to the uncontrollable growth of cancer.

The Forth lab examines the physical forces exerted by components of cellular structures like the mitotic spindle. The spindle is formed when two centrosomes, take a position on opposite sides of the two newly created, and hopefully identical, sets of chromosomes massed near the center of the cell. A dense network of microtubules extends from the centrosomes, forming a cage that surrounds and connects the chromosomes. Then the microtubules - aided by millions of proteins and motor proteins - begin to shorten and slide, pulling the chromosomes toward the centrosomes, until the two sets have been separated.

PRC1 is a "cross-linker," a long, springy molecule with a head at either end that links two microtubules along their length. Near the center of the mitotic spindle, large quantities of PRC1 link groups of microtubules into bundles.

Forth's team created a controlled version of the microtubule sliding mechanism in the lab and used an optical trapping technique to measure the frictional force PRC1 exerts between the sliding microtubules. Optical trapping relies on a tightly focused laser beam which attracts an object - in this case, a miniscule polystyrene bead - attached to the microtubule. The researchers use the laser beam to pull on the bead - similar to the "tractor beam" of science fiction - and convert the shift in refracted light as the bead resists the pull of the trap into a direct measure of force.

The team also tagged PRC1 with a fluorescent molecule, allowing them to observe its shifting movement and distribution as the microtubules were pulled apart. They used total internal reflection fluorescence microscopy to collect images of the experiment while simultaneously recording the forces.

Forth and his colleagues found that, as more of the protein is added into the system, the microtubules meet more resistance as they move faster. Essentially, PRC1 behaves like a glue holding the cell together.

"Like a lot of biological processes, it's a bit of a Goldilocks problem," Forth said. "If you don't have this protein, you're in trouble, because the cell fails at division. If you have too much, we think that it gums up the works and holds everything together too much, which may be how this protein is linked to cancer. There's a sort of sweet spot in healthy cell division, where there's just the right amount controlling the rates carefully and precisely."

"This research reveals the inner workings of a fundamental mechanism of biology, providing knowledge that better positions us to defeat cancer," said Curt Breneman, dean of the School of Science. "It's a carefully and beautifully designed study, the results of which have created a foundation on which future anti-cancer strategies can be built."

"The mitotic crosslinking protein PRC1 acts like a mechanical dashpost to resist microtubule sliding" was published in Developmental Cell. Forth was joined in the research by RPI graduate students Ignas Gaska, April Alfieri, and RPI undergraduate student Mason Armstrong.
-end-
About Rensselaer Polytechnic Institute

Founded in 1824, Rensselaer Polytechnic Institute is America's first technological research university. Rensselaer encompasses five schools, 32 research centers, more than 145 academic programs, and a dynamic community made up of more than 7,900 students and over 100,000 living alumni. Rensselaer faculty and alumni include more than 145 National Academy members, six members of the National Inventors Hall of Fame, six National Medal of Technology winners, five National Medal of Science winners, and a Nobel Prize winner in Physics. With nearly 200 years of experience advancing scientific and technological knowledge, Rensselaer remains focused on addressing global challenges with a spirit of ingenuity and collaboration. To learn more, please visit http://www.rpi.edu.

Rensselaer Polytechnic Institute

Related Breast Cancer Articles from Brightsurf:

Oncotarget: IGF2 expression in breast cancer tumors and in breast cancer cells
The Oncotarget authors propose that methylation of DVDMR represents a novel epigenetic biomarker that determines the levels of IGF2 protein expression in breast cancer.

Breast cancer: AI predicts which pre-malignant breast lesions will progress to advanced cancer
New research at Case Western Reserve University in Cleveland, Ohio, could help better determine which patients diagnosed with the pre-malignant breast cancer commonly as stage 0 are likely to progress to invasive breast cancer and therefore might benefit from additional therapy over and above surgery alone.

Partial breast irradiation effective treatment option for low-risk breast cancer
Partial breast irradiation produces similar long-term survival rates and risk for recurrence compared with whole breast irradiation for many women with low-risk, early stage breast cancer, according to new clinical data from a national clinical trial involving researchers from The Ohio State University Comprehensive Cancer Center - Arthur G.

Breast screening linked to 60 per cent lower risk of breast cancer death in first 10 years
Women who take part in breast screening have a significantly greater benefit from treatments than those who are not screened, according to a study of more than 50,000 women.

More clues revealed in link between normal breast changes and invasive breast cancer
A research team, led by investigators from Georgetown Lombardi Comprehensive Cancer Center, details how a natural and dramatic process -- changes in mammary glands to accommodate breastfeeding -- uses a molecular process believed to contribute to survival of pre-malignant breast cells.

Breast tissue tumor suppressor PTEN: A potential Achilles heel for breast cancer cells
A highly collaborative team of researchers at the Medical University of South Carolina and Ohio State University report in Nature Communications that they have identified a novel pathway for connective tissue PTEN in breast cancer cell response to radiotherapy.

Computers equal radiologists in assessing breast density and associated breast cancer risk
Automated breast-density evaluation was just as accurate in predicting women's risk of breast cancer, found and not found by mammography, as subjective evaluation done by radiologists, in a study led by researchers at UC San Francisco and Mayo Clinic.

Blood test can effectively rule out breast cancer, regardless of breast density
A new study published in PLOS ONE demonstrates that Videssa® Breast, a multi-protein biomarker blood test for breast cancer, is unaffected by breast density and can reliably rule out breast cancer in women with both dense and non-dense breast tissue.

Study shows influence of surgeons on likelihood of removal of healthy breast after breast cancer dia
Attending surgeons can have a strong influence on whether a patient undergoes contralateral prophylactic mastectomy after a diagnosis of breast cancer, according to a study published by JAMA Surgery.

Young breast cancer patients undergoing breast conserving surgery see improved prognosis
A new analysis indicates that breast cancer prognoses have improved over time in young women treated with breast conserving surgery.

Read More: Breast Cancer News and Breast Cancer Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.